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Abstract
The mTOR (mammalian target of rapamycin) signal transduction pathway integrates various signals, regulating ribosome
biogenesis and protein synthesis as a function of available energy and amino acids, and assuring an appropriate coupling of
cellular proliferation with increases in cell size. In addition, recent evidence has pointed to an interplay between the mTOR
and p53 pathways. We investigated the genetic variability of 67 key genes in the mTOR pathway and in genes of the p53
pathway which interact with mTOR. We tested the association of 1,084 tagging SNPs with prostate cancer risk in a study of
815 prostate cancer cases and 1,266 controls nested within the European Prospective Investigation into Cancer and
Nutrition (EPIC). We chose the SNPs (n=11) with the strongest association with risk (p,0.01) and sought to replicate their
association in an additional series of 838 prostate cancer cases and 943 controls from EPIC. In the joint analysis of first and
second phase two SNPs of the PRKCI gene showed an association with risk of prostate cancer (ORallele=0.85, 95% CI 0.78–
0.94, p=1.3610
23 for rs546950 and ORallele=0.84, 95% CI 0.76–0.93, p=5.6610
24 for rs4955720). We confirmed this in a
meta-analysis using as replication set the data from the second phase of our study jointly with the first phase of the Cancer
Genetic Markers of Susceptibility (CGEMS) project. In conclusion, we found an association with prostate cancer risk for two
SNPs belonging to PRKCI, a gene which is frequently overexpressed in various neoplasms, including prostate cancer.
Citation: Campa D, Hu ¨sing A, Stein A, Dostal L, Boeing H, et al. (2011) Genetic Variability of the mTOR Pathway and Prostate Cancer Risk in the European
Prospective Investigation on Cancer (EPIC). PLoS ONE 6(2): e16914. doi:10.1371/journal.pone.0016914
Editor: Irina Agoulnik, Florida International University, United States of America
Received October 6, 2010; Accepted January 1, 2011; Published February 23, 2011
Copyright:  2011 Campa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16914Funding: Specific results of this study were obtained with financial support from the US Army Medical Research and Material Command (W81XWH-05-1-0156). http://
cdmrp.army.mil/pcrp/default.shtml. The EPIC study was funded by "Europe Against Cancer" Programme of the European Commission (SANCO); Ligue contre le Cancer
(France); Socie ´te ´ 3M (France); Mutuelle Ge ´ne ´rale de l’Education Nationale; Institut National de la Sante ´ et de la Recherche Me ´dicale (INSERM); German Cancer Aid;
German Cancer Research Center; German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of
Health; the participating regional governments and institutions of Spain; Cancer Research UK; Medical Research Council, UK; Hellenic Ministry of Health and Social
Solidarity; the Stavros Niarchos Foundation and the Hellenic Health Foundation; Italian Association for Research on Cancer; Italian National Research Council; Dutch
Ministry of Public Health, Welfare and Sports (VWS), Dutch Ministry of Health, Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch
ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF) (The Netherlands); Statistics Netherlands; Swedish Cancer Society; Swedish Scientific Council;
Regional Government of Skane, Sweden; Norwegian Cancer Society. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: r.kaaks@dkfz.de
Introduction
Within the prostate tissue, tumor-promoting effects of endog-
enous hormones and growth factors are thought to be associated
with the stimulation of cellular growth and mitosis, and inhibition
of apoptosis. In addition to signaling by IGF-I (but also insulin,
and other growth factors), the growth and proliferation of cells are
co-determined by amounts of energy and essential amino acids
available to the cell [1,2,3].
Recent studies have showed that the mTOR (mammalian target
of rapamycin) signal transduction pathway integrates these various
signals, regulating ribosome biogenesis and protein synthesis as a
function of available energy and amino acids, and assuring an
appropriate coupling of cellular proliferation with increases in cell
size [1,2]. The mTOR pathway is regulated through a cascade of
enzymatic phosphorylation reactions through phosphatidyl-inosi-
tol-triphosphate kinase (PI3K)/protein kinase B (PKB-AKT1),
atypical protein kinase C (aPKC), AMP-activated protein kinase
(AMPK), hamartin/tuberin (encoded respectively by the tuberous
sclerosis complex-1 (TSC1) and 2 (TSC2) genes), ras-homologue
enriched in brain (Rheb), regulatory associated protein with
mTOR (raptor), and mammalian target of rapamycin (mTOR).
mTOR activation in turn leads to phosphorylation of downstream
elements that directly control ribosome biogenesis and ribosomal
mRNA translation for protein synthesis[4,5,6,7,8,9,10,11,12,13,
14,15,16]. Supplementary figure S1 shows a simplified scheme of
the mTOR pathway.
This pathway includes several established proto-oncogenes
(PI3K, AKT1) and tumor suppressor genes (PTEN – which reduces
mTOR activity through inhibition of PI3K/AKT1 – TSC1, TSC2).
These genes are often mutated or aberrantly expressed in human
malignancies, including prostate tumors[9,17,18,19,20,21,22,23].
In addition, recent evidence has pointed to an interesting
interplay between the mTOR and p53 pathways (reviewed by
Levine et al., 2006) [24]. There are two major connections
between these pathways, leading to altered response to stress
signals after activation of p53, through activation of AMPK, TSC2
and a p53 phosphatase, composed of an alpha-4 subunit and the
PP2A catalytic subunit.
We hypothesized that genes in the mTOR pathway and genes
of the p53 pathway that directly relate to mTOR may be centrally
implicated in prostate carcinogenesis, and that polymorphic alleles
in these genes could modify their expression or activity, thus
conferring altered prostate cancer susceptibility. SNPs in genes
belonging to the mTOR pathway have already been studied in
relation to cancer risk, with some promising results [25,26,27].
In this report we investigated the genetic variability of 67 key
genes in the above mentioned pathways. We tested the association
of 1,084 tagging SNPs with prostate cancer risk in a case-control
study nested within the European Prospective Investigation into
Cancer and Nutrition (EPIC). To our knowledge this is the first
report on polymorphisms of these genes and prostate cancer
risk.
Results
Summary characteristics of the study populations are shown in
table 1. In the first phase of this study we analyzed 1,084 SNPs in
67 genes involved in the mTOR pathway (as summarized in
supplementary table S1) in 815 prostate cancer cases and 1,266
matched controls. We replicated the best hits in an independent
population consisting of 838 prostate cancer cases and 943
matched controls.
Genotyping success rates and quality control
We had 1,163 SNPs on our GoldenGate array, of which 30
were included as quality controls and 1,133 were in the candidate
gene regions of interest in this study. Thirty-four SNPs were
dropped because they had a call rate lower than 75%, which is
usually indicative of poor genotyping quality. Eleven SNPs (1% of
the total) showed strong departure from Hardy-Weinberg
Equilibrium (p,10
25) and were thus not analyzed further. Four
SNPs were monomorphic in this population. This left a total of
1,084 SNPs (96% of those selected initially) in the 67 candidate
genes to be analyzed.
The average call rate of the 1,084 SNPs used for statistical
analysis was 99.8% (range 85.2%–100%).
Thirty SNPs were included, which had previously been
genotyped on the same samples in the context of a different
study. The concordance of the new genotypes with the old
genotypes was 100%.
We initially included 2,099 samples, and after removing subjects
samples with a call rate lower than 75% (n=39), we had a dataset
including 815 prostate cancer cases and 1,239 controls. The
incidence density sampling led to duplicate selection of 27 controls
so that 1,266 controls were included in the conditional analyses.
Random duplicate samples (,5%) were also included and
concordance of their genotypes was 100.0%.
Main effects of genotyped SNPs
Eleven SNPs were significantly associated with prostate cancer
risk, at a threshold of p,0.01 (ptrend,0.01 or p2df,0.01)
(rs520820 in GADD45A; rs546950 and rs4955720 in PRKCI;
rs706711, rs13156223 and rs831123 in PIK3R1; rs6797860
inTP63; rs11763144 in PRKAG2; rs388372 in RPS6KA2;
rs13337626 in TSC2; rs3783501 in GADD45B). Supplementary
table S2 shows detailed results for all 1,084 SNPs.
Replication
We genotyped the eleven SNPs from the first phase in an
additional set of 838 prostate cancer cases and 943 matched
controls. In the second phase SNP rs546950 in the PRKCI gene
mTOR Polymorphisms and Prostate Cancer Risk
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risk, at the conventional threshold of p,0.05 (p2df=0.02).
When we analyzed jointly the results from the two sample sets,
both PRKCI SNPs showed an association with risk (ORallele=0.84,
95% CI=0.76–0.93, p2df=0.0028, ptrend=0.0007 for rs4955720;
ORallele=0.86, 95% CI=0.78–0.95, p2df=0.0014, ptrend=0.0020
for rs546950). Results for the first phase, the replication set and for
the joint analysis are shown in table 2.
We calculated Meff values for each candidate gene separately
and for the whole study (by adding the individual gene Meff values;
details are shown in supplementary table S3). The pathway-wide
Meff was 849. We therefore used a study-wide significance p-
threshold of 0.05/849=5.9610
25. Using this threshold, no
significant associations (ptrend,5.9.x10
25 or p2df,5.9610
25) were
observed between any of the polymorphisms genotyped and
overall prostate cancer risk.
The two SNPs in PRKCI were also genotyped in the context of
the Cancer Genetic Markers of Susceptibility (CGEMS) project
(http://cgems.cancer.gov/), one of the first genome-wide associ-
ation studies on prostate cancer susceptibility. The associations
observed in the first phase of CGEMS (ORallele=0.85
ptrend=0.0024 for rs4955720, ORallele=0.94 ptrend=0.089 for
rs546950) were similar to those observed in the present report. In a
meta-analysis using the unconditional OR-estimate from the data
of the second phase of our study jointly with results from CGEMS,
the two SNPs showed very similar results as those obtained with
the EPIC data alone (ORallele=0.91, 95% CI 0.83–0.99, p=0.029
for rs546950 and ORallele=0.87, 95% CI 0.79–0.95, p=0.002 for
rs4955720). A meta-analysis performed considering the joint data
of the first and second phase of our study with results from
CGEMS showed essentially the same results (ORallele=0.91, 95%
CI 0.84–0.98, p=0.019 for rs546950 and ORallele=0.85, 95% CI
0.78–0.92, p=0.00016 for rs4955720).
Effects of genotyped SNPs in subgroups of disease
aggressiveness
We analyzed associations of SNPs with prostate cancer risk by
grouping cases according to disease aggressiveness, but we did not
observe statistically significant (p,0.05) heterogeneity between
strata. Results for the eleven SNPs that were genotyped on the
complete dataset are shown in supplementary table S4.
Discussion
The mTOR pathway is implicated in tumor development, and
analogues of rapamycin – a natural antibiotic that specifically
interferes with mTOR action (via an additional receptor protein) –
are showing great promise as potential therapeutic agents for
treating certain types of solid tumors [28,29,30]. We hypothesized
that genes belonging to the mTOR pathway may be centrally
implicated in cancer development, including prostate cancer, and
that polymorphic alleles of these genes might affect prostate cancer
risk.
In this study, we thoroughly captured common genetic variation
across 67 genes in the mTOR pathway and to our knowledge, this
is the most comprehensive evaluation of common and coding
variation in the mTOR pathway genes in relation with prostate
cancer risk. We found an association of two SNPs in the PRKCI
gene, rs546950 and rs4955720, with a decreased risk of prostate
cancer. The first SNP showed an association at the first screening,
in a replication set and in a meta-analysis of our second phase with
data from CGEMS, while rs4955720 showed an association only
in the screening set and in the meta-analysis. Since the two SNPs
were selected as tagging SNPs they are not in strong LD, however
we cannot exclude that they might reflect the same signal due to a
moderate underlying LD (r
2 between the two SNPs is 0.53).
A role of genetic variation in the PRKCI gene in prostate cancer
aetiology is plausible given that atypical protein kinase C lambda/
iota (aPKCl/i), encoded by the PRKCI gene, is a protein kinase C
isozyme, which plays multifunctional roles in cellular maintenance
and growth of epithelial cells[31,32,33,34,35,36,37]. One of the
physiological functions of aPKCl/i is to mediate insulin-induced
increases in glucose transport. Insulin regulates glucose transport
through phosphatidyl-inositol-triphosphate kinase (PI3K). Distal
effectors of PI3K include protein kinase B (PKB/Akt) and aPKC
isoforms f and l/i [38].
PKC isozymes are also involved in cell proliferation, survival,
differentiation and apoptosis. Studies on lung, ovary, colon, and
breast cancers have demonstrated a relationship between aPKCl/
i expression and cancer progression and suggest that aPKCl/i
expression might predict poor survival[21,22,23,39,40,41,42,43].
There are several reports showing enhanced aPKCl/i expression
in human prostate cancer tissues, but the relationship between
aPKCl/i and prostate cancer progression remains un-
clear[44,45]. Furthermore experiments using the prostate cancer
Table 1. Characteristics of the study populations.
Phase I Controls Cases
1,266 815
Age at recruitment (Median, Mean,Std) 60.5 (61.3,6.1) 60.4 (60.7,5.8)
Severity of disease
a
Non-aggressive - 657
Aggressive - 158
Phase II Controls Cases
943 838
Age at recruitment (Median, Mean,Std) 59.9 (59.3, 6.3) 59.8 (59.1, 6.5)
Severity of disease
a
Non-aggressive - 748
Aggressive - 90
aDisease aggressiveness was defined as extraprostatic extension (stage C/D) or high histologic grade (Gleason score $8).
doi:10.1371/journal.pone.0016914.t001
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cancer growth both in vivo and in vitro [46]. Overexpression of
aPKCl/i can be explained with an amplification of the PRCKI
gene, which has been reported in lung and ovarian cancer
[22,23,39] or the amplification of chromosome 3q including the
PRCKI gene which has been reported in prostate cancer cell lines
[47]. Another possibility is that aPKCl/i expression is up-
regulated through the transcriptional activation of PRCKI
promoter [48].
In this report we found that two allelic variants of the PRKCI
gene were associated at a study-wise significant level with a
decreased risk of prostate cancer. rs546950 and rs4955720 are not
situated in the coding region of the gene and it is not immediately
evident how to relate the genetic variability to the gene function.
We searched public databases for any reported functions of the
two SNPs but we did not find evidence pointing to a differential
gene expression or mRNA stability. No report to date has been
published on either SNP in relation to disease suceptibility. We
also ran in silico analysis on the possible changes on trasciption
binding sites. These analyses predict a differential binding to the
alleles of the two SNPs of various transcription factors. In
particular MYOD1 is predicted to bind only to the minor allele
(A) of rs546950 and POU3F3 to the minor allele (A) of rs4955720.
Both transcription factors have pro-differentiation, anti-prolifera-
tion effect [49,50]. The fact that both of them bind to the minor,
protective alleles is intriguing, although MYOD1 and POU3F3
Table 2. SNPs genotyped in the first and second phase of the project.
Gene Study Cases/Controls ORhet(95%CI)
b ORhom(95%CI)
b ORallele(95%CI)
b p2df ptrend
rs number phase AA/AB/BB
a AA/AB/BB
a
GADD45A
c 1 500/259/32 690/423/69 0.82 (0.67–1.01) 0.60 (0.39–0.94) 0.80 (0.68–0.94) 0.0274 0.0079
rs520820 2 432/277/29 427/267/44 1.03 (0.83–1.27) 0.64 (0.39–1.05) 0.93 (0.78–1.10) 0.1859 0.3784
1+2 938/539/61 1124/692/113 0.92 (0.79–1.06) 0.62 (0.45–0.87) 0.86 (0.76–0.97) 0.0156 0.0117
GADD45B 1 181/432/167 349/576/241 1.47 (1.18–1.84) 1.32 (1.01–1.74) 1.16 (1.02–1.33) 0.0033 0.0253
rs3783501 2 213/350/178 219/361/161 1.00 (0.79–1.26) 1.13 (0.86–1.50) 1.06 (0.92–1.22) 0.5853 0.4163
1+2 397/786/347 570/945/402 1.22 (1.04–1.43) 1.23 (1.01–1.49) 1.11 (1.01–1.23) 0.0368 0.0273
PIK3R1 1 475/258/57 708/424/48 0.94 (0.77–1.15) 1.82 (1.21–2.72) 1.13 (0.96–1.32) 0.0073 0.1365
rs13156223 2 397/279/46 416/270/36 1.07 (0.87–1.32) 1.32 (0.84–2.07) 1.11 (0.94–1.31) 0.4275 0.2245
1+2 876/542/103 1132/695/84 1.01 (0.88–1.17) 1.59 (1.18–2.15) 1.12 (1.00–1.26) 0.0096 0.0423
PIK3R1 1 261/356/174 393/608/181 0.92 (0.75–1.14) 1.52 (1.16–1.99) 1.19 (1.04–1.36) 0.0004 0.0105
rs706711 2 223/362/149 235/364/135 1.05 (0.83–1.32) 1.17 (0.87–1.59) 1.08 (0.93–1.25) 0.5901 0.3272
1+2 485/725/324 631/975/319 0.99 (0.84–1.15) 1.35 (1.11–1.65) 1.14 (1.03–1.26) 0.0026 0.0107
PIK3R1 1 660/118/13 942/232/8 0.74 (0.58–0.94) 2.29 (0.89–5.90) 0.85 (0.68–1.06) 0.0082 0.1393
rs831123 2 582/117/7 582/116/8 1.01 (0.76–1.33) 0.88 (0.32–2.42) 0.99 (0.77–1.28) 0.9660 0.9489
1+2 1250/236/20 1529/352/16 0.83 (0.70–1.00) 1.48 (0.74–2.94) 0.90 (0.76–1.06) 0.0636 0.1994
PRKAG2 1 611/163/17 838/314/30 0.72 (0.58–0.89) 0.77 (0.42–1.41) 0.77 (0.64–0.92) 0.0101 0.0047
rs11763144 2 559/174/8 551/177/13 0.97 (0.76–1.23) 0.61 (0.25–1.48) 0.93 (0.75–1.15) 0.5400 0.4781
1+2 1178/338/25 1397/492/43 0.82 (0.70–0.97) 0.72 (0.44–1.19) 0.83 (0.72–0.95) 0.0310 0.0086
PRKCI 1 339/356/96 421/568/193 0.77 (0.63–0.93) 0.62 (0.47–0.83) 0.78 (0.68–0.90) 0.0017 0.0004
rs4955720 2 272/332/109 247/349/117 0.86 (0.68–1.09) 0.85 (0.62–1.16) 0.91 (0.78–1.06) 0.3768 0.2078
1+2 613/694/206 675/917/312 0.82 (0.70–0.95) 0.72 (0.58–0.89) 0.84 (0.76–0.93) 0.0028 0.0007
PRKCI 1 278/384/129 347/588/246 0.79 (0.65–0.98) 0.66 (0.50–0.86) 0.81 (0.71–0.92) 0.0068 0.0017
rs546950 2 250/333/156 207/384/148 0.70 (0.55–0.90) 0.85 (0.63–1.15) 0.91 (0.78–1.05) 0.0160 0.1898
1+2 528/723/288 558/975/396 0.76 (0.65–0.89) 0.76 (0.62–0.92) 0.86 (0.78–0.95) 0.0014 0.0020
RPS6KA2 1 263/419/109 481/527/174 1.48 (1.20–1.82) 1.17 (0.87–1.56) 1.16 (1.01–1.33) 0.0011 0.0317
rs388372 2 264/330/80 264/322/88 1.02 (0.81–1.29) 0.91 (0.64–1.29) 0.97 (0.83–1.14) 0.7920 0.7419
1+2 531/754/189 748/854/263 1.25 (1.07–1.46) 1.05 (0.84–1.31) 1.08 (0.97–1.19) 0.0120 0.1674
TP63 1 356/340/43 561/442/101 1.21 (0.98–1.48) 0.65 (0.44–0.96) 0.97 (0.83–1.13) 0.0051 0.6897
rs6797860 2 377/301/50 376/294/58 1.02 (0.82–1.27) 0.86 (0.57–1.29) 0.97 (0.82–1.14) 0.7161 0.7040
1+2 740/648/96 947/746/159 1.11 (0.96–1.29) 0.77 (0.58–1.01) 0.97 (0.87–1.09) 0.0238 0.6576
TSC2 1 650/133/5 1029/144/5 1.49 (1.15–1.94) 1.62 (0.46–5.68) 1.46 (1.14–1.87) 0.0090 0.0024
rs13337626 2 629/110/4 612/122/9 0.88 (0.67–1.17) 0.44 (0.14–1.43) 0.84 (0.65–1.08) 0.2756 0.1650
1+2 1289/243/9 1649/268/14 1.15 (0.95–1.39) 0.77 (0.33–1.80) 1.10 (0.93–1.31) 0.2829 0.2767
aAA=homozygotes for the common allele; AB=heterozygotes; BB=homozygotes for the rare allele.
bResults of conditional logistic regression. ORhet=odds ratios for the heterozygotes vs. the homozygotes for the common allele; ORhom=odds ratios for the
homozygotes for the rare allele vs. the homozygotes for the common allele; ORallele=odds ratios for an increase of one rare allele; 95%CI=95% confidence interval.
cFor each SNP, the first line indicates results of the first phase, second line shows results of the replication phase, and third line indicates results of the joint analysis.
doi:10.1371/journal.pone.0016914.t002
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in the brain, respectively. rs546950 is situated in the first intron of
PRKCI, very close to the beginning of the gene, therefore this is
consistent with a possible involvement in the regulation of
transcription of the gene. Since the variant allele exerts a
protective effect on prostate cancer risk we can hypothesize that
it decreases or increases the ability of transcription factors to bind
and in such way that results in a decrease of the gene expression,
and consequently decreasing the risk of prostate cancer.
It is more difficult to understand the association between
rs4955720 and decreased risk of prostate cancer from a biological
point of view. However, in the joint analysis the p value of this SNP
was the more significant of the two. This SNP is located at the 39 of
the gene, after the end of the last exon, and a possible function is not
immediately evident. Also the possible differential binding with
transcription factors seems to be less relevant in this case. rs4955720
could be in high linkage disequilibrium (LD) with another SNP that
directly affects the transcription and/or function of PRKCI. However,
all known common PRKCI SNPs in high LD with rs4955720 are
located in introns of the gene, and do not seem functionally relevant.
In conclusion it is difficult to understand the biological mechanism
that could explain the association of the two polymorphism with
prostate cancer risk and further functional studies are warranted.
SNPs of some of the PI3K genes we investigated here were also
studied in the Breast and Prostate Cancer Cohort Consortium
(BPC3) (Koutros 2010). In that study, rs7556371, a SNP of PIK3C2B,
was shown to be associated with increased prostate cancer risk. In our
study we genotyped rs4951384, which tags rs7556371 (r
2=1), but we
did not observe any evidence of association (supplementary table S2).
However, it has to be noticed that the increase of risk found by
Koutros et al was very modest and could therefore be detected only
by a study with a huge sample size, such as BPC3.
The intensive SNP tagging approach used provided a close to
exhaustive analysis of possible mono-allelic (main effect) associa-
tions of prostate cancer risk with common polymorphic variants
known for each of the loci studied. We had sufficient power (0.80
for codominant model in the joint analysis) to detect OR=1.40 (or
OR=0.71 for associations with a reduced risk) at al-
pha=5.9610
25 (study-wide significance p-threshold) for a SNP
with a minor allele frequency of 0.30.
Although over 97% of the EPIC subjects are estimated to be of
Caucasian origin, differences in allelic frequencies across Europe
could in theory cause confounding by population stratification.
However, we did not observe major variations in allele frequencies
across countries for the SNP studied here (data not shown).
A possible drawback of this work is the large number of tests
performed, although several hints suggest a real association: 1) we
observed associations (p,0.05) in both stages of the study, 2) after
correcting for the number of tests (n=11) performed in the second
phase the association between rs546950 and prostate cancer risk
remains significant, 3) the association is biologically plausible and 4)
the meta-analysis CGEMS/EPIC (2,743 cases and 3,088 controls)
showed very similar results as those obtained with the EPIC data
alone (p=0.002 for rs4955720 and p=0.029 for rs546950.
In conclusion, we found an association with prostate cancer risk
for two SNPs belonging to PRKCI, a gene which is frequently
overexpressed in various cancers, including prostate cancer. This
observation warrants replication in a larger study.
Materials and Methods
Ethics Statement
All participants signed an informed written consent. The study
was approved by the ethical review boards of the International
Agency for Research on Cancer, and of the collaborating
institutions responsible for subject recruitment in each of the
EPIC recruitment centres.
The EPIC cohort
A fully detailed description of the EPIC cohort has been
published elsewhere [51]. Briefly, EPIC consists of about 370,000
women and 150,000 men, aged 35–69, recruited between 1992
and 2005 in 10 Western European countries.
The vast majority (.97%) of subjects recruited in the EPIC
cohort are of European (‘Caucasian’) origin. All EPIC study
subjects provided anthropometric measurements (height, weight,
and waist and hip circumferences) and extensive, standardized
questionnaire information about medical history, diet, physical
activity, smoking, and other lifestyle factors. About 260,000
women and 140,000 men provided a blood sample.
Cases of cancer occurring after recruitment into the cohort and
blood donation are identified through local and national cancer
registries in 7 of the 10 countries, and in France, Germany, and
Greece by a combination of contacts with national health
insurances and/or active follow-up through the study subjects or
their next of kin. Follow-up on vital status is achieved through
record linkage with mortality registries.
Selection of case and control subjects
Case subjects were selected among men who developed prostate
cancer after blood collection. Control subjects (1–2 controls per
case) were selected randomly by incidence density sampling,
matching the cases for centre of recruitment, age at blood
donation and duration of follow-up. A total of 815 invasive
prostate cancer cases and 1,266 controls, for a total of 2,081
subjects, were included in the first phase of the present study. Each
control should have been free of cancer up to the duration of
follow-up of the index case.
SNP selection
For each of the 67 candidate genes we selected a genomic
region between 5 kb 59 of the beginning of the first known exon
and 5 kb 39 of the end of the last known exon. A list of SNPs in all
67 gene regions was compiled using data from HapMap (release
22, based on dbSNP version 126 and NCBI genome build 36), and
tagging SNPs were selected by use of the Tagger algorithm[52], as
implemented in the Haploview software. Parameters used for
Tagger selection were minor allele frequency $5% in Caucasians,
minimum r
2=0.8 between each pair of tagged and tagging SNPs,
pairwise tagging (we observed an average mean r
2 between tagging
SNPs and the SNPs they tag of 0.95). SNPs that were predicted to
perform poorly with Illumina GoldenGate genotyping technology
were either replaced by SNPs in high LD (r
2=0.8, as calculated
from HapMap data), or dropped from the list if no proxy was
available. This gave us a list of 1,133 SNPs. Finally, for quality
control purpose, we added 30 SNPs that had been genotyped on
the same samples in an unrelated project.
Sample preparation and genotyping
DNA was extracted from blood samples on an Autopure
instrument (Qiagen, Hilden, Germany) with Puregene chemistry
(Qiagen, Hilden, Germany). The order of DNAs from cases and
controls was randomized on PCR plates in order to ensure that an
equalnumber ofcases and controls couldbe analyzed simultaneously.
Genotyping was carried out using the Illumina GoldenGate
technology (San Diego, CA, USA), according to the protocol
specified by the manufacturer.
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Any sample where greater than 25% of the SNPs failed had all
of the SNPs set to missing and these subjects were dropped from
analysis. We then filtered data to remove poorly performing SNPs:
all SNPs that failed on 25% of samples or more were set to
missing, as were all SNPs that showed statistically significant
(p,10
25) deviations from Hardy-Weinberg equilibrium (HWE)
among controls.
We analyzed the association between prostate cancer risk and
genotypes for each SNP using conditional logistic regression.
Genotypes were coded either as counts of minor alleles (trend test)
or as two indicator variables, one for heterozygotes and one for
minor-allele homozygotes (two degrees of freedom test).
We performed also analyses in subgroups of disease aggressive-
ness (aggressive disease was defined as extraprostatic extension
(stage C/D) or high histologic grade (Gleason score $8).
All statistical analyses were performed using SAS 9.11.
In order to take into account the large number of tests
performed in this project, we calculated for each gene the number
of effective independent variables, Meff, by use of the SNP Spectral
Decomposition approach [53]. We obtained a gene-wide Meff
value for each gene and also a study-wide Meff value, by adding up
the gene Meff’s.
Replication
We replicated the SNPs showing the strongest associations with
prostate cancer risk (ptrend,0.01 or p2df,0.01; n=11) on an
additional set of 838 cases and 943 controls selected within the
EPIC cohort. All the additional genotyping was carried out using
the Taqman assay. The MGB Taqman probes and primers were
purchased from Applied Biosystems (Foster City, CA) as pre-
designed assays. The reaction mix included 10 ng genomic DNA,
10 pmol each primer, 2 pmol each probe and 2.5 ml of 2x master
mix (Applied Biosystems) in a final volume of 5 ml. The
thermocycling included 40 cycles with 30 s at 95uC followed by
60 s at 60uC. PCR plates were read on an ABI PRISM 7900HT
instrument (Applied Biosystems).
All samples that did not give a reliable result in the first round of
genotyping were resubmitted to up to two additional rounds of
genotyping. Data points that were still not filled after this
procedure were left blank. Repeated quality control genotypes
(5% of the total) showed a concordance of 100.0%.
Bioinformatic analysis
Potential binding sites of transcription factors within the
sequence encompassing the two study-wise significantly associated
SNPs were performed with MatInspector Professional (http://
genomatix.de/cgi-bin/matinspector_prof/mat_fam.pl) [54].
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Table S1 Candidate genes and their SNPs.
(DOC)
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